feed,title,long_url,short_url
Benzinga,Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks,https://benzinga.com/general/biotech/21/11/24189410/ascendis-hypoparathyroidism-candidate-shows-durable-benefit-at-84-weeks,https://j.mp/3HEUa0Y
